CD19 and myeloid sarcoma: To address this issue B cell surface markers CD19 and CD27 were analyzed in LCLs from healthy controls and MS donors, either treated with IFN-β or not at the time of phlebotomy, to evaluate B cell subset phenotype distributions [43] (Fig. 1).